Managing the patient with acute liver failure
Filipe S. Cardoso, Constantine J. Karvellas – 20 April 2017
Significance of measured intraoperative portal vein flows after thrombendvenectomy in deceased donor liver transplantations with portal vein thrombosis
Mark Draoua, Nicole Titze, Amar Gupta, Hoylan T. Fernandez, Michael Ramsay, Giovanna Saracino, Gregory McKenna, Giuliano Testa, Goran B. Klintmalm, Peter T. W. Kim – 20 April 2017 – Adequate portal vein (PV) flow in liver transplantation is essential for a good outcome, and it may be compromised in patients with portal vein thrombosis (PVT). This study evaluated the impact of intraoperatively measured PV flow after PV thrombendvenectomy on outcomes after deceased donor liver transplantation (DDLT).
Hepatic fibrosis in children and adults
Rebecca G. Wells – 20 April 2017
Transplanting patients with active bacterial infection
Elizabeth C. Verna, Marcus R. Pereira – 20 April 2017
Treatment of HCV in persons who inject drugs: Treatment as prevention
Jason Grebely, Gregory J. Dore – 20 April 2017
Biomarkers and imaging studies to predict portal hypertension and varices
Christine K. Lee – 20 April 2017
Liver retransplantation: Recurrent primary sclerosing cholangitis may provide better outcomes
Jennie Choe, David C. Mulligan – 20 April 2017
Hepatic steatosis after pediatric liver transplant
Emily R. Perito, Tabitha Vase, Rageshree Ramachandran, Andrew Phelps, Kuang‐Yu Jen, Robert H. Lustig, Vickie A. Feldstein, Philip Rosenthal – 20 April 2017 – Hepatic steatosis develops after liver transplantation (LT) in 30% of adults, and nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in nontransplanted children. However, posttransplant steatosis has been minimally studied in pediatric LT recipients. We explored the prevalence, persistence, and association with chronic liver damage of hepatic steatosis in these children.
Biomarkers and imaging studies to predict portal hypertension and varices
Christine K. Lee – 20 April 2017
A simplified multivisceral transplantation procedure for patients with combined end‐stage liver disease and type 2 diabetes mellitus
Xiao‐Shun He, Shun‐Jun Fu, Qiang Zhao, Xiao‐Feng Zhu, Dong‐Ping Wang, Ming Han, Wei‐Qiang Ju, Yi Ma, Xing‐Yuan Jiao, Xiao‐Peng Yuan, An‐Bin Hu, Zhi‐Yong Guo – 19 April 2017 – In liver transplant patients with type 2 diabetes mellitus (DM), the disease worsens after transplantation because of longterm use of diabetogenic immunosuppressive drugs, making management of those patients a great challenge.